Literature DB >> 21727930

Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?

M Wasif Saif, John Chabot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21727930     DOI： 10.1038/nrclinonc.2011.107

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.

Authors:  Muhammad Wasif Saif
Journal:  JOP       Date:  2008-03-08

2.  Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

Authors:  Thierry Conroy; Bernard Paillot; Eric François; Roland Bugat; Jacques-Henri Jacob; Ulrich Stein; Salvador Nasca; Jean-Philippe Metges; Olivier Rixe; Pierre Michel; Emmanuelle Magherini; Aliette Hua; Gael Deplanque
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

5.  Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

Authors:  C N Mallinson; M O Rake; J B Cocking; C A Fox; M T Cwynarski; B L Diffey; G A Jackson; J Hanley; V J Wass
Journal:  Br Med J       Date:  1980-12-13

6.  Advancements in the management of pancreatic cancer.

Authors:  Jia Li; Muhammad Wasif Saif
Journal:  JOP       Date:  2009-03-09

7.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

8.  Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.

Authors:  Muhammad Wasif Saif
Journal:  JOP       Date:  2007-07-09

9.  A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

Authors:  C Yoo; J Y Hwang; J-E Kim; T W Kim; J S Lee; D H Park; S S Lee; D W Seo; S K Lee; M-H Kim; D J Han; S C Kim; J-L Lee
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640
  9 in total
  9 in total

Review 1.  Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Authors:  Jie-Er Ying; Li-Ming Zhu; Bi-Xia Liu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.

Authors:  Masamichi Mizuma; Zeshaan A Rasheed; Shinichi Yabuuchi; Noriyuki Omura; Nathaniel R Campbell; Roeland F de Wilde; Elizabeth De Oliveira; Qing Zhang; Oscar Puig; William Matsui; Manuel Hidalgo; Anirban Maitra; N V Rajeshkumar
Journal:  Mol Cancer Ther       Date:  2012-07-02       Impact factor: 6.261

3.  Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.

Authors:  Begoña Díaz; Katherine T Ostapoff; Jason E Toombs; Jason Lo; Michael Y Bonner; Adam Curatolo; Volkan Adsay; Rolf A Brekken; Jack L Arbiser
Journal:  Oncotarget       Date:  2016-08-09

4.  Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Authors:  Takahiro Akahori; Masayuki Sho; Hiroaki Yanagimoto; Sohei Satoi; Minako Nagai; Satoshi Nishiwada; Kenji Nakagawa; Kota Nakamura; Tomohisa Yamamoto; Satoshi Hirooka; So Yamaki; Naoya Ikeda
Journal:  Oncologist       Date:  2019-01-24

5.  The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.

Authors:  A Arlt; H Schäfer; H Kalthoff
Journal:  Oncogenesis       Date:  2012-11-26       Impact factor: 7.485

6.  Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.

Authors:  Masafumi Ikeda; Akihiro Sato; Nobuo Mochizuki; Kayo Toyosaki; Chika Miyoshi; Rumi Fujioka; Shuichi Mitsunaga; Izumi Ohno; Yusuke Hashimoto; Hideaki Takahashi; Hiromi Hasegawa; Shogo Nomura; Ryuji Takahashi; Satoshi Yomoda; Katsuya Tsuchihara; Satoshi Kishino; Hiroyasu Esumi
Journal:  Cancer Sci       Date:  2016-12-19       Impact factor: 6.716

7.  Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study.

Authors:  Yasuhiro Hagiwara; Yasuo Ohashi; Takuji Okusaka; Hideki Ueno; Tatsuya Ioka; Narikazu Boku; Shinichi Egawa; Takashi Hatori; Junji Furuse; Kazuhiro Mizumoto; Shinichi Ohkawa; Taketo Yamaguchi; Kenji Yamao; Akihiro Funakoshi; Ann-Lii Cheng; Kiyohiro Kihara; Atsushi Sato; Masao Tanaka
Journal:  ESMO Open       Date:  2017-03-15

8.  Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation.

Authors:  Shoki Sato; Toru Nakamura; Toyomasa Katagiri; Takahiro Tsuchikawa; Toshihiro Kushibiki; Kouji Hontani; Mizuna Takahashi; Kazuho Inoko; Hironobu Takano; Hirotake Abe; Shintaro Takeuchi; Masato Ono; Shota Kuwabara; Kazufumi Umemoto; Tomohiro Suzuki; Osamu Sato; Yusuke Nakamura; Satoshi Hirano
Journal:  Oncotarget       Date:  2017-10-19

Review 9.  Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Doudou Li; Changhao Chen; Yu Zhou; Rufu Chen; Xinxiang Fan; Zhuofei Bi; Zhihua Li; Yimin Liu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.